Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 3,177,223 Units at a price of C$0.20 per Unit (the "Offering Price") for aggregate gross proceeds of $635,444.60. 

Each Unit is comprised of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of C$0.28 for a period of four (4) years from the date of issuance.

The Company paid an arm's length finder a cash fee of C$13,500 and issued to the finder 67,500 warrants attributable to investors introduced to the Company by the finder within 3 months following such introduction ("Finder Warrants"). Each Finder Warrant entitles the Finder to purchase one Common Share at an exercise price of C$0.28 for a period of four (4) years from the date of issuance.

Iris Bincovich Innocan Pharma's CEO stated: "I am thrilled with this successful closing of this private placement round, which reflects strong investor confidence in Innocan's long-term vision, strategic direction as well as our proprietary CBD-loaded liposome platform technology (LPT) and our strongly growing consumer wellness operations. These new funds raised will allow us to further advance our innovative LPT through its regulatory milestones, and furthers our long-term goal of enhancing health and wellness worldwide."

The Company intends to use the proceeds from the Offering for working capital and general corporate purposes.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or pursuant to an exemption from such registration requirements.